AlphaYou
Overview
Smart money at a glance
Filings to Oct 1, 2026No insider open-market trades in 90 days (SEC Form 4). Congress: net selling of $1K to $15K in 180 days.
- Company insidersSEC Form 4, last 90 days
- $0No open-market trades
- CongressSTOCK Act, last 180 days
- -$1K to -$15K netNet selling
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 6 added, 1 cutMore adding
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Key stats
Fundamentals Sep 30- Open
- $525.26
- 52-wk high
- $560.25
- High
- $529.72
- 52-wk low
- $400.74
- Low
- $522.74
- Prev close
- $526.73
- Mkt cap
- $133.51B
- P/E
- 30.7x
- Volume
- 1.15M
- Fwd P/E
- 24.1x
- Beta
- 0.32
- P/S
- 10.6x
- P/B
- 6.5x
- Profit margin
- +35.0%
- Op margin
- +38.1%
- ROE
- +23.5%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about VRTX filings
Are insiders buying or selling Vertex Pharmaceuticals Inc (VRTX) stock?
Neither. Vertex Pharmaceuticals Inc (VRTX) insiders filed no open-market purchases or sales in the 90 days to Oct 1, 2026, according to SEC Form 4 filings.
Which members of Congress have traded VRTX recently?
Rep. David J. Taylor (R) sold $1K to $15K on Aug 26, 2026, disclosed 10 days later. In total, 1 member disclosed 1 VRTX trade with trade dates in the last 180 days, filed a median 10 days after trading.
How current is this VRTX smart-money data?
This summary uses filings available on Oct 1, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Buys/Adds (2)
- AQ
AQR
$229.0M
added
- MI
Millennium
$218.9M
added
Sells/Trims (1)
- DS
D.E. Shaw
$109.6M
trimmed
What insiders are doing
What Congress is doing
Sells (2)
How top traders are positioned
No tracked top-trader positions in VRTX right now.
Live Hyperliquid positioning - not every stock is covered
Activist stakes, short interest & more
Earnings
Earnings came in 1.2% above what analysts expected.
Earnings per share
$4.15 expected
Revenue
$3.22B expected
Company adjusted EPS
From the company's release
Compared on the analyst basis, which counts earnings differently from the company.
GAAP EPS was $4.31 and adjusted EPS was $4.73. The adjusted figure is comparable to consensus.
FY2026 guidance
$13.10B to $13.20B
No comparable estimate
Reports Nov 2, 2026, in 32 days
Estimates as of Sep 30, 2026
EPS expected
-$29.56 to $5.06
Revenue expected
12 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
What the company said
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $3.08B | $3.23B | $2.99B | $3.33B |
| Cost of what it sold | $414.8M | $466.0M | $392.8M | $489.2M |
| Gross profit | $2.66B | $2.76B | $2.59B | $2.84B |
| What it spent | ||||
| Research and development | $1.03B | $973.7M | $961.6M | $993.8M |
| Sales and admin | $445.1M | $487.0M | $493.7M | $582.2M |
| Other operating costs | — | — | — | $21.8M |
| Total operating expenses | $1.48B | $1.46B | $1.46B | $1.60B |
| What was left | ||||
| Operating profit | $1.19B | $1.30B | $1.14B | $1.25B |
| Interest on debt | $3.3M | $3.3M | — | — |
| Profit before tax | $1.30B | $1.33B | $1.25B | $1.39B |
| Tax | $215.9M | $139.9M | $221.5M | $292.0M |
| Net profit | $1.08B | $1.19B | $1.03B | $1.10B |
| EBITDA | $1.36B | $1.39B | $1.31B | $1.39B |
Technicals
Price structure
This stock is trending upward.
Trend
Constructive
60 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
$100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth This Much Today
NeutralSep 29UBS Raises Vertex Pharmaceuticals Price Target to $615 From $585, Maintains Buy Rating
BullishSep 29Vertex Pharmaceuticals Price Target Raised to $615.00/Share From $585.00 by UBS
BullishSep 29Vertex Pharmaceuticals Incorporated (VRTX) latest stock news and headlines
NeutralSep 29Could Vertex Pharmaceuticals (VRTX)’s Kidney Breakthrough Unlock a New Opportunity for Maze Therapeutics (MAZE)?
BullishSep 29VRTX Maintains Buy Rating by UBS -- Price Target Raised to $615
BullishSep 28Vertex Pharmaceuticals stock last trades at USD 526.66 on September 28, 2026
Leans bullishSep 28UBS raises Vertex stock price target to $615 on kidney drug trial
BullishSep 28
Macro
21 macro signals shaping VRTX right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results